BioWorld BioWorld MedTech BioWorld Asia BioWorld Science

BioWorld

New year sees Abbvie, Zelgen in $1.1B T-cell engager deal
Abbvie Inc. signed a $1.1 billion New Year’s Eve deal with China’s Zelgen Biopharmaceuticals Co. Ltd., gaining ex-China rights to Zelgen’s lead oncology asset, alveltamig...

More in BioWorld

BioWorld MedTech

Med techs prune, purchase to rebalance product portfolios
Four optimization trends dominated the med-tech industry in 2025. Growth-driven acquisitions propelled major players into hot markets, while strategic realignments at...

More in BioWorld MedTech

BioWorld Science

Science in 2025: the best of the rest
A review of 2025's noteworthy advances in medical research, including GLP-1 receptor agonists as anti-aging drugs, tumor-agnostic therapies and xenotransplants.

More in BioWorld Science

BioWorld Asia

China approves Innovent’s ipilimumab for colon cancer
China’s National Medical Products Administration approved Innovent Biologics Inc.’s NDA for Tabosun (ipilimumab N01, IBI-310) in combination with sintilimab as neoadjuvant...

More in BioWorld Asia

BioWorld Insider podcast

The opioid crisis may not be front and center anymore, but it’s raging still. Elysium Therapeutics Inc. CEO Greg Sturmer talks about his firm’s candidate for a solution to the medical and societal problem.